Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function.
Chitra C Iyer, Deepti Chugh, Prameela J Bobbili...
https://pubmed.ncbi.nlm.nih.gov/33964607/Actively Recruiting
Led by Unlimited Biotechnology LLC · Updated on 2026-07-13
12
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating the safety and tolerability of a gene therapy using AAV9-Follistatin alone or combined with a VEGF plasmid to address age-related muscle decline. This Phase 12a open-label study involves adults aged 35 to 75 years with muscle loss, focusing on safety and early signs of muscle mass and function improvement. Participants will be assigned sequentially to one of three groups low-dose AAV-Follistatin monotherapy, high-dose AAV-Follistatin monotherapy, or combination therapy with VEGF plasmid followed by AAV-Follistatin. Treatments are given through intramuscular injections in major muscles, with rapamycin administered for about two months to reduce immune reactions. The combination group receives VEGF plasmid twice before a delayed AAV-Follistatin dose. The study uses a cautious 33 dose-escalation design with safety reviews between cohorts. Participants undergo screening including medical history, physical exams, lab tests, and muscle assessments such as DXA and strength tests. The core study period lasts about 90 days 120 days for the combination group with frequent safety and function monitoring. Optional follow-up visits at 6 and 12 months are available. Researchers measure treatment side effects, immune responses, muscle performance, and safety outcomes, with independent oversight to manage risks. Total participation may extend up to 12 months.
CONDITIONS
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
I
Ivan Morgunov
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Unlimited Biotechnology LLC
Lead Sponsor
Global Alliance for Regenerative Medicine
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 7 days
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 90 to 120 days depending on group
Participants receive intramuscular injections of AAV-Follistatin gene therapy alone or combined with VEGF plasmid, with rapamycin given for about two months to reduce immune reactions. Treatment doses and schedules vary by group, including single and sequential injections.
Frequent safety and functional assessments
Duration - Up to 12 months
Participants may opt into extended safety monitoring at approximately 6 and 12 months after treatment to assess long-term effects.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Chitra C Iyer, Deepti Chugh, Prameela J Bobbili...
https://pubmed.ncbi.nlm.nih.gov/33964607/Jerry R Mendell, Zarife Sahenk, Vinod Malik...
https://pubmed.ncbi.nlm.nih.gov/25322757/Ruhang Tang, Natalia S Harasymowicz, Chia-Lung Wu...
https://pubmed.ncbi.nlm.nih.gov/32426485/Janaiah Kota, Chalonda R Handy, Amanda M Haidet...
https://pubmed.ncbi.nlm.nih.gov/20368179/Samiah A Al-Zaidy, Zarife Sahenk, Louise R Rodino-Klapac...
https://pubmed.ncbi.nlm.nih.gov/27858738/Tuisku Suoranta, Nihay Laham-Karam, Seppo Ylä-Herttuala
https://pubmed.ncbi.nlm.nih.gov/39086961/Michael E Nance, Ruicheng Shi, Chady H Hakim...
https://pubmed.ncbi.nlm.nih.gov/31327755/Jerry R Mendell, Zarife Sahenk, Samiah Al-Zaidy...
https://pubmed.ncbi.nlm.nih.gov/28279643/Roman Deev, Igor Plaksa, Ilia Bozo...
https://pubmed.ncbi.nlm.nih.gov/29996720/Roman Deev, Igor Plaksa, Ilia Bozo...
https://pubmed.ncbi.nlm.nih.gov/28050885/Unlimited Biotechnology LLC
Lead Sponsor
Global Alliance for Regenerative Medicine
Collaborating Sponsor